ClinicalTrials.gg
CompletedNCT02788279Updated Dec 11, 2019Results posted

A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)

A Phase 3 interventional study of Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody and Cobimetinib in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 73 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-11.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
363
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing atezolizumab in Colorectal Neoplasms — 4 open to participants now, 8 under way, 3 of them phase 3. atezolizumab · Colorectal Neoplasms.

Enrollment
3rd of 19
363 · median 80
Started
2016
with 2 others
Phase 3
4 of 19
1 open now
Registered
2nd of 19
by date
Lead sponsor
3 of 19
Hoffmann-La Roche

Among the 19 studies testing atezolizumab in Colorectal Neoplasms, this one is the 3rd largest by enrollment, is one of 3 that started in 2016, is one of 4 in phase 3, and was the 2nd registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

4 of the 19 studies testing atezolizumab in Colorectal Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About atezolizumab

atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing atezolizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This is a Phase III, multicenter, open-label, three-arm, randomized study in participants with unresectable locally advanced or metastatic colorectal cancer (CRC) who have received at least two prior regimens of cytotoxic chemotherapy for metastatic disease. The study compares regorafenib, a standard of care therapy in this setting, to cobimetinib plus atezolizumab and atezolizumab monotherapy.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Locally advanced or Metastatic colorectal adenocarcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Disease-specific inclusion criteria:

  • confirmed adenocarcinoma originating from the colon or rectum (Stage 4 American Joint Committee on Cancer [AJCC] 7th edition)
  • Experienced disease progression or was intolerant to at least two systemic chemotherapy regimens for colorectal cancer that must have included fluroropyrimidines, irinotecan, and oxaliplatin; adjuvant regimen can be considered as one chemotherapy regimen for metastatic disease if the participant had disease recurrence within 6 months of completion; disease progression must have occurred within 3 months of the last systemic therapy administration

General inclusion criteria:

  • (ECOG) performance status of 0 or 1
  • Anticipated greater than or equal to (>=) 3 months
  • Adequate hematologic and end organ function
  • Women of must agree to appropriately use an effective form of (failure rate of less than [\<] 1 percent [%] per year) during the treatment period, within 5 months after the last dose of atezolizumab, and within 3 months after the last dose of cobimetinib and regorafenib
  • Men must agree not to donate sperm or have intercourse with a female partner without using appropriate barrier contraception during the treatment period and for 3 months after the last dose of either cobimetinib or regorafenib
  • Provide an archival or newly obtained tumor tissue sample

Exclusion criteria

Exclusion Criteria:

  • After the approximate 5% cap for microsatellite (MSI)-high participants is reached, only MSI-stable participants will be eligible
  • Once the 50% cap for wild-type RAS has been reached, only extended RAS-mutant participants will be eligible
  • Major surgery or radiotherapy within 21 days prior to Cycle 1 Day 1 or anticipation of needing such procedure while receiving study treatment
  • Treatment with any anti-cancer agent within 14 days prior to Cycle 1 Day 1
  • Uncontrolled tumor-related pain. Participants requiring narcotic pain medication must be on a stable regimen at study entry
  • Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage more than once every 28 days. Indwelling drainage catheters (e.g., PleurX®) are allowed
  • Active or untreated central nervous system (CNS) are excluded
  • Prior therapy with any cancer immunotherapy, MEK inhibitor, or regorafenib
  • Participants with active (other than CRC) or a prior malignancy within the past 3 years are excluded. Participants with completely resected cutaneous melanoma (early stage), basal cell carcinoma, cutaneous squamous cell carcinoma, cervical carcinoma in-situ, breast carcinoma in-situ, and localized prostate cancer are eligible
  • Unstable angina, new onset angina within last 3 months, myocardial infarction within last 6 months and current congestive heart failure Class II or higher
  • (LVEF) below institutional lower limit of normal or below 50%, whichever is lower
  • Poorly controlled hypertension, defined as a blood pressure consistently above 150/90 millimeters of Mercury (mmHg) despite optimal medical management
  • (HIV) infection
  • Active tuberculosis infection
  • Severe infections within 2 weeks prior to Cycle 1 Day 1
  • Active or chronic viral or C infection
  • History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for central serous retinopathy, retinal vein occlusion, or neovascular macular degeneration
  • Participants will be excluded if they currently have any of the risk factors as defined in the study protocol for retinal vein occlusion
  • History of disease
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, bronchiolitis obliterans, drug-induced pneumonitis, or idiopathic pneumonitis
  • History of organ transplantation including bone marrow transplantation
  • Inability to swallow medications
  • Malabsorption condition that would alter the absorption of orally administered medications
  • Pregnant, lactating, breastfeeding, or intending to become pregnant during the study
  • Administration of a live, attenuated vaccine within 4 weeks before randomization or anticipation of a will be required during the study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
363 participants (actual)

Study arms

  • Experimental
    Atezolizumab

    Participants will receive atezolizumab monotherapy 1200 milligrams (mg) intravenous (IV) on Day 1 in a 21-day cycle until disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.

    Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody

  • Experimental
    Cobimetinib + Atezolizumab

    Participants will receive cobimetinib 60 mg orally on Days 1 to 21 plus atezolizumab 840 mg IV on Day 1 and Day 15 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.

    Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody · Drug: Cobimetinib

  • Active comparator
    Regorafenib

    Participants will receive regorafenib 160 mg orally on Days 1 to 21 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.

    Drug: Regorafenib

Interventions

  • Participants will receive atezolizumab IV at 840 mg on Day 1 and Day 15 in a 28-day cycle as a combination therapy or at 1200 mg on Day 1 in a 21-day cycle as a monotherapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.

  • Participants will receive cobimetinib 60 mg orally on Days 1 to 21 in a 28-day cycle as a combination therapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.

  • Participants will receive regorafenib 160 mg orally on Days 1 to 21 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall survival is defined as the time (in months) between the date of randomization and the date of death due to any cause. Participants who were not reported as having died at the date of analysis were censored at the date when they were last known to be alive. Participants who did not have post-baseline information were censored at the date of randomization + 1 day. Median OS was estimated by Kaplan-Meier method and 95% CI was assessed using the method of Brookmeyer and Crowley.

    Time frame: From randomization up to death due to any cause (up to approximately 20 months)

Secondary outcomes

  1. Progression-Free Survival (PFS) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

    PFS was defined as the time from randomization to disease progression as determined by the investigator with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression. Participants who did not have post-baseline information were censored at the date of randomization + 1 day. Median OS was estimated by Kaplan-Meier method and 95% CI was assessed using the method of Brookmeyer and Crowley.

    Time frame: From randomization up to disease progression or death due to any cause (up to approximately 20 months)

  2. Percentage of Participants With Investigator-Assessed Objective Response of Complete Response (CR) or Partial Response (PR) According to RECIST Version 1.1

    PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions). Objective response and its 95% CI were calculated using the Clopper-Pearson method.

    Time frame: From randomization up to death due to any cause (up to approximately 20 months)

  3. Duration of Response (DOR) According to RECIST Version 1.1

    DOR is defined as the period measured from the date of the first occurrence of a CR or PR (whichever status is recorded first) until the first date that progressive disease or death is documented. Disease progression was determined on the basis of investigator assessment with use of RECIST v1.1. Median DOR was estimated using the Kaplan-Meier method, and the 95% CI was calculated using the method of Brookmeyer and Crowley.

    Time frame: From first occurrence of CR or PR up to disease progression or death due to any cause (up to approximately 20 months)

  4. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life-C30 Questionnaire (EORTC QLQ-C30) Physical Functioning Sub-scale Score

    The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.

    Time frame: Baseline, end of the study (up to approximately 2.5 years)

  5. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life-C30 Questionnaire (EORTC QLQ-C30) Global Quality of Life Sub-scale Score at the End of the Study

    The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.

    Time frame: Baseline, end of the study (up to approximately 2.5 years)

  6. Percentage of Participants With Adverse Events (AEs)

    Time frame: Baseline, end of the study (up to approximately 2.5 years)

  7. Plasma Concentration of Cobimetinib

    Time frame: Predose (0 hours) and 3 to 6 hours after dose on Day 15 of Cycles 1 and 4 (1 cycle = 28 days) (up to approximately 2.5 years).

  8. Serum Concentration of Atezolizumab

    Pre-infusion (0 hours) on Day 1 of Cycles 1 to 4; 30 minutes post-infusion on Day 1 of Cycles 1 and 4; pre-infusion (0 hours) on Day 1 of Cycle 8 and every 8 cycles thereafter; at treatment discontinuation; 120 days after treatment discontinuation (up to approximately 2.5 years) (1 cycle = 28 days)

    Time frame: Pre-infusion (0 hours) on Day 1 of Cycle 1 up to approximately 2.5 years. Detailed time frame is explained in the outcome measure description field.

  9. Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab

    Time frame: Pre-infusion (0 hours) on Day 1 of Cycles 1 to 4, 8, and every 8 cycles thereafter; at treatment discontinuation; 120 days after treatment discontinuation (up to approximately 2.5 years) (1 cycle = 28 days)

07

Results

Posted Jun 18, 2019

Participant flow

A total of 490 participants were screened of whom only 363 participants were randomized.

Participant flow — Overall Study
MilestoneRegorafenibCobimetinib + AtezolizumabAtezolizumab
Started9018390
Received treatment (safety population)8017990
Modified itt population5712561
Completed000
Not completed9018390
Withdrew: Death6213672
Withdrew: Withdrawal by subject10155
Withdrew: Lost to follow-up032
Withdrew: Sponsor decision182911

Outcome measures

PrimaryOverall Survival (OS)

Overall survival is defined as the time (in months) between the date of randomization and the date of death due to any cause. Participants who were not reported as having died at the date of analysis were censored at the date when they were last known to be alive. Participants who did not have post-baseline information were censored at the date of randomization + 1 day. Median OS was estimated by Kaplan-Meier method and 95% CI was assessed using the method of Brookmeyer and Crowley.

Time frame:
From randomization up to death due to any cause (up to approximately 20 months)
Reported as:
Median · months
Overall Survival (OS)
monthsRegorafenibCobimetinib + AtezolizumabAtezolizumab
Overall Survival (OS)8.51 (6.41 to 10.71)8.87 (7.00 to 10.61)7.10 (6.05 to 10.05)
Statistical analysis
  • Regorafenib vs Cobimetinib + Atezolizumab · Stratified Log-Rank · p = 0.9871 · Hazard ratio (hr): 1.00 · 95% CI 0.73 to 1.38Hazard ratio was estimated using stratified Cox regression.
  • Regorafenib vs Atezolizumab · Stratified Log-Rank · p = 0.3360 · Hazard ratio (hr): 1.19 · 95% CI 0.83 to 1.71Hazard ratio was estimated using stratified Cox regression.
  • Regorafenib vs Cobimetinib + Atezolizumab · Unstratified Log-Rank · p = 0.9686 · Hazard ratio (hr): 1.01 · 95% CI 0.74 to 1.38Hazard ratio was estimated using unstratified Cox regression.
  • Regorafenib vs Atezolizumab · Unstratified Log-Rank · p = 0.3553 · Hazard ratio (hr): 1.18 · 95% CI 0.83 to 1.69Hazard ratio was estimated using unstratified Cox regression.
SecondaryProgression-Free Survival (PFS) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

PFS was defined as the time from randomization to disease progression as determined by the investigator with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression. Participants who did not have post-baseline information were censored at the date of randomization + 1 day. Median OS was estimated by Kaplan-Meier method and 95% CI was assessed using the method of Brookmeyer and Crowley.

Time frame:
From randomization up to disease progression or death due to any cause (up to approximately 20 months)
Reported as:
Median · months
Progression-Free Survival (PFS) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
monthsRegorafenibCobimetinib + AtezolizumabAtezolizumab
Progression-Free Survival (PFS) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)2.00 (1.87 to 3.61)1.91 (1.87 to 1.97)1.94 (1.91 to 2.10)
Statistical analysis
  • Regorafenib vs Cobimetinib + Atezolizumab · Stratified Log-Rank · p = 0.1208 · Hazard ratio (hr): 1.25 · 95% CI 0.94 to 1.65Hazard ratio was estimated using stratified Cox regression.
  • Regorafenib vs Atezolizumab · Stratified Log-Rank · p = 0.0509 · Hazard ratio (hr): 1.39 · 95% CI 1.00 to 1.94Hazard ratio was estimated using stratified Cox regression.
  • Regorafenib vs Cobimetinib + Atezolizumab · Unstratified Log-Rank · p = 0.1726 · Hazard ratio (hr): 1.21 · 95% CI 0.92 to 1.60Hazard ratio was estimated using unstratified Cox regression.
  • Regorafenib vs Atezolizumab · Unstratified Log-Rank · p = 0.0467 · Hazard ratio (hr): 1.39 · 95% CI 1.00 to 1.91Hazard ratio was estimated using unstratified Cox regression.
SecondaryPercentage of Participants With Investigator-Assessed Objective Response of Complete Response (CR) or Partial Response (PR) According to RECIST Version 1.1

PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions). Objective response and its 95% CI were calculated using the Clopper-Pearson method.

Time frame:
From randomization up to death due to any cause (up to approximately 20 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Investigator-Assessed Objective Response of Complete Response (CR) or Partial Response (PR) According to RECIST Version 1.1
percentage of participantsRegorafenibCobimetinib + AtezolizumabAtezolizumab
Percentage of Participants With Investigator-Assessed Objective Response of Complete Response (CR) or Partial Response (PR) According to RECIST Version 1.12.2 (0.27 to 7.80)2.7 (0.89 to 6.26)2.2 (0.27 to 7.80)
Statistical analysis
  • Regorafenib vs Cobimetinib + Atezolizumab · Stratified Cochrane-Mantel-Haenszel · p = 1.0000 · Difference in response rates: 0.51 · 95% CI -3.92 to 4.9495% CI for difference in response rates was constructed using Hauck-Anderson method.
  • Regorafenib vs Atezolizumab · Stratified Cochran-Mantel-Haenszel · p = 1.0000 · Difference in response rates: 0.00 · 95% CI -4.89 to 4.8995% CI for difference in response rates was constructed using Hauck-Anderson method.
SecondaryDuration of Response (DOR) According to RECIST Version 1.1

DOR is defined as the period measured from the date of the first occurrence of a CR or PR (whichever status is recorded first) until the first date that progressive disease or death is documented. Disease progression was determined on the basis of investigator assessment with use of RECIST v1.1. Median DOR was estimated using the Kaplan-Meier method, and the 95% CI was calculated using the method of Brookmeyer and Crowley.

Time frame:
From first occurrence of CR or PR up to disease progression or death due to any cause (up to approximately 20 months)
Reported as:
Median · months
Duration of Response (DOR) According to RECIST Version 1.1
monthsRegorafenibCobimetinib + AtezolizumabAtezolizumab
Duration of Response (DOR) According to RECIST Version 1.14.50 (3.61 to 5.39)1.97 (1.77 to 3.81)2.81 (1.84 to 3.78)
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life-C30 Questionnaire (EORTC QLQ-C30) Physical Functioning Sub-scale Score

The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.

Time frame:
Baseline, end of the study (up to approximately 2.5 years)
Reported as:
Mean · units of a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life-C30 Questionnaire (EORTC QLQ-C30) Physical Functioning Sub-scale Score
units of a scaleRegorafenibCobimetinib + AtezolizumabAtezolizumab
Week 3——-1.50 ± 10.56
Week 4-6.52 ± 13.90-3.92 ± 11.05—
Week 6——-0.14 ± 12.49
Week 8-8.97 ± 13.95-3.23 ± 16.15—
Week 9——-6.67 ± 17.19
Week 12-7.78 ± 13.57-5.10 ± 15.54-6.40 ± 16.61
Week 15——-7.08 ± 14.90
Week 16-9.12 ± 17.10-5.11 ± 16.67—
Week 18——-3.70 ± 14.95
Week 20-7.92 ± 19.51-0.87 ± 14.95—
Week 21——-8.33 ± 17.37
Week 24-5.45 ± 9.81-3.00 ± 18.670.00 ± 16.87
Week 27——0.95 ± 15.60
Week 28-5.00 ± 9.92-3.16 ± 15.29—
Week 30——-8.00 ± 20.76
Week 32-4.67 ± 11.35-10.74 ± 21.10—
Week 33——-1.67 ± 13.74
Week 36-12.22 ± 14.25-1.78 ± 16.234.44 ± 15.40
Week 39——2.22 ± 19.25
Week 40-5.00 ± 11.39-0.61 ± 16.18—
Week 42——4.44 ± 15.40
Week 441.67 ± 3.333.33 ± 16.07—
Week 45——4.44 ± 15.40
Week 48-13.33 ± 6.671.82 ± 9.470.00 ± 18.86
Week 51——0.00 ± 18.86
Week 52-5.00 ± 6.383.64 ± 10.05—
Week 54——0.00 ± 18.86
Week 56-2.22 ± 3.855.00 ± 13.69—
Week 57——0.00 ± 18.86
Week 60-3.33 ± 4.712.96 ± 11.600.00 ± 18.86
Week 64-6.67 ± 18.86-2.67 ± 10.11—
Week 68—0.00 ± 0.00—
Treatment Discontinuation-17.00 ± 19.21-16.24 ± 23.49-11.79 ± 19.01
Long Term Follow Up Month 3-22.29 ± 24.29-15.11 ± 16.80-20.00 ± 26.67
Long Term Follow Up Month 6-14.07 ± 17.14-10.00 ± 14.14-8.00 ± 15.92
Long Term Follow Up Month 30—-20.00 ± NA13.33 ± NA
Long Term Follow Up Month 33—-20.00 ± NA13.33 ± NA
Long Term Follow Up Month 36—-20.00 ± NA13.33 ± NA
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life-C30 Questionnaire (EORTC QLQ-C30) Global Quality of Life Sub-scale Score at the End of the Study

The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.

Time frame:
Baseline, end of the study (up to approximately 2.5 years)
Reported as:
Mean · units of a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life-C30 Questionnaire (EORTC QLQ-C30) Global Quality of Life Sub-scale Score at the End of the Study
units of a scaleRegorafenibCobimetinib + AtezolizumabAtezolizumab
Week 3——-1.70 ± 17.76
Week 4-6.44 ± 18.84-7.00 ± 21.24—
Week 6——-4.86 ± 17.43
Week 8-8.05 ± 15.98-4.38 ± 22.58—
Week 9——-4.84 ± 15.78
Week 12-1.04 ± 18.60-4.25 ± 18.51-3.67 ± 15.42
Week 15——-4.69 ± 12.16
Week 16-4.39 ± 18.08-1.94 ± 23.64—
Week 18——7.41 ± 18.37
Week 200.52 ± 18.384.71 ± 23.28—
Week 21——6.25 ± 19.29
Week 24-3.79 ± 20.193.75 ± 23.95-6.94 ± 19.31
Week 27——-2.38 ± 19.07
Week 28-8.33 ± 17.250.00 ± 31.18—
Week 30——5.00 ± 15.14
Week 32-5.00 ± 14.801.39 ± 23.79—
Week 33——6.25 ± 17.18
Week 360.00 ± 7.455.56 ± 16.8616.67 ± 25.00
Week 39——22.22 ± 17.35
Week 402.08 ± 10.4911.36 ± 12.51—
Week 42——25.00 ± 16.67
Week 440.00 ± 13.619.52 ± 15.63—
Week 45——19.44 ± 9.62
Week 48-2.78 ± 4.8110.61 ± 15.858.33 ± 0.00
Week 51——8.33 ± 0.00
Week 524.17 ± 15.9612.12 ± 17.62—
Week 54——12.50 ± 5.89
Week 56-5.56 ± 9.6218.75 ± 9.71—
Week 57——8.33 ± 0.00
Week 60-4.17 ± 17.6816.67 ± 15.598.33 ± 0.00
Week 64-4.17 ± 5.896.67 ± 24.58—
Week 68—0.00 ± NA—
Treatment Discontinuation-19.87 ± 23.93-14.27 ± 25.98-14.53 ± 20.48
Long Term Follow-up Month 3-21.30 ± 28.60-6.11 ± 22.15-11.36 ± 20.16
Long Term Follow-up Month 6-13.89 ± 19.09-15.83 ± 15.44-11.67 ± 15.14
Long Term Follow-up Month 30—0.00 ± NA8.33 ± NA
Long Term Follow-up Month 33—0.00 ± NA8.33 ± NA
Long Term Follow-up Month 36—0.00 ± NA8.33 ± NA
SecondaryPercentage of Participants With Adverse Events (AEs)
Time frame:
Baseline, end of the study (up to approximately 2.5 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs)
percentage of participantsRegorafenibCobimetinib + AtezolizumabAtezolizumab
Serious AEs23.839.716.7
Non-serious AEs97.597.893.3
SecondaryPlasma Concentration of Cobimetinib
Time frame:
Predose (0 hours) and 3 to 6 hours after dose on Day 15 of Cycles 1 and 4 (1 cycle = 28 days) (up to approximately 2.5 years).
Reported as:
Geometric mean · Nanogram/milliliter (ng/mL)
Plasma Concentration of Cobimetinib
Nanogram/milliliter (ng/mL)Cobimetinib + Atezolizumab
Cycle 1 Day 15 - Predose195 ± 190.0
Cycle 1 Day 15 - Postdose362 ± 89.4
Cycle 4 Day 15 - Predose94.3 ± 741.9
Cycle 4 Day 15 - Postdose210 ± 273.4
SecondarySerum Concentration of Atezolizumab

Pre-infusion (0 hours) on Day 1 of Cycles 1 to 4; 30 minutes post-infusion on Day 1 of Cycles 1 and 4; pre-infusion (0 hours) on Day 1 of Cycle 8 and every 8 cycles thereafter; at treatment discontinuation; 120 days after treatment discontinuation (up to approximately 2.5 years) (1 cycle = 28 days)

Time frame:
Pre-infusion (0 hours) on Day 1 of Cycle 1 up to approximately 2.5 years. Detailed time frame is explained in the outcome measure description field.
Reported as:
Geometric mean · microgram/milliliter (ug/mL)
Serum Concentration of Atezolizumab
microgram/milliliter (ug/mL)AtezolizumabCobimetinib + Atezolizumab
Cycle 1 Day 1 - PredoseNA ± NANA ± NA
Cycle 1 Day 1 - 30 min post dose348 ± 150.0259 ± 141.0
Cycle 2 Day 1 - Predose81.5 ± 35.768.2 ± 191.2
Cycle 2 Day 1 - 30 min post dose56.2 ± NA—
Cycle 3 Day 1 - Predose118 ± 45.4133 ± 51.2
Cycle 4 Day 1 - Predose146 ± 52.4167 ± 48.4
Cycle 4 Day 1 - 30 min post dose487 ± 41.5415 ± 37.2
Cycle 5 Day 1 - Predose155 ± NA—
Cycle 5 Day 1 - 30 min post dose456 ± NA—
Cycle 8 Day 1 - Predose138 ± 54.6198 ± 52.6
Cycle 16 Day 1 - Predose226 ± 24.4264 ± NA
Treatment Discontinuation97.9 ± 114.576.6 ± 184.9
Unscheduled0.784 ± 2159.50.539 ± NA
SecondaryPercentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab
Time frame:
Pre-infusion (0 hours) on Day 1 of Cycles 1 to 4, 8, and every 8 cycles thereafter; at treatment discontinuation; 120 days after treatment discontinuation (up to approximately 2.5 years) (1 cycle = 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab
percentage of participantsCobimetinib + AtezolizumabAtezolizumab
Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab43.841.3

Adverse events

Collected over From baseline to end of study (approximately 2.5 years).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Regorafenib62/90 (68.9%)19/90 (21.1%)78/80 (97.5%)
Cobimetinib + Atezolizumab136/183 (74.3%)71/183 (38.8%)173/179 (96.6%)
Atezolizumab72/90 (80%)15/90 (16.7%)81/90 (90%)
Most frequent serious events
Showing 10 of 89
Most frequent serious events
EventRegorafenibCobimetinib + AtezolizumabAtezolizumab
PYREXIAGeneral disorders3/8012/1792/90
DIARRHOEAGastrointestinal disorders3/806/1790/90
ANAEMIABlood and lymphatic system disorders0/805/1790/90
ABDOMINAL PAINGastrointestinal disorders2/802/1791/90
INTESTINAL PERFORATIONGastrointestinal disorders2/801/1790/90
SEPSISInfections and infestations2/804/1790/90
INFUSION RELATED REACTIONInjury, poisoning and procedural complications0/803/1790/90
ATRIAL FIBRILLATIONCardiac disorders1/800/1790/90
LEFT VENTRICULAR DYSFUNCTIONCardiac disorders1/800/1790/90
ANAL HAEMORRHAGEGastrointestinal disorders1/800/1790/90
Most frequent other events
Showing 10 of 57
Most frequent other events
EventRegorafenibCobimetinib + AtezolizumabAtezolizumab
DIARRHOEAGastrointestinal disorders30/80115/17917/90
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROMESkin and subcutaneous tissue disorders42/803/1791/90
FATIGUEGeneral disorders38/8065/17924/90
RASHSkin and subcutaneous tissue disorders17/8085/1798/90
DECREASED APPETITEMetabolism and nutrition disorders34/8049/17921/90
NAUSEAGastrointestinal disorders12/8067/17919/90
HYPERTENSIONVascular disorders25/809/1794/90
PYREXIAGeneral disorders20/8053/17912/90
VOMITINGGastrointestinal disorders9/8052/17913/90
ABDOMINAL PAINGastrointestinal disorders21/8030/17913/90

Baseline characteristics

Age, Continuous
Age, Continuous(Years)RegorafenibCobimetinib + AtezolizumabAtezolizumabTotal
Mean58.4 ± 10.358.0 ± 11.956.7 ± 10.257.8 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)RegorafenibCobimetinib + AtezolizumabAtezolizumabTotal
Female397531145
Male5110859218
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RegorafenibCobimetinib + AtezolizumabAtezolizumabTotal
Hispanic or Latino911525
Not Hispanic or Latino7716682325
Unknown or Not Reported46313
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RegorafenibCobimetinib + AtezolizumabAtezolizumabTotal
American Indian or Alaska Native0000
Asian12181141
Native Hawaiian or Other Pacific Islander0112
Black or African American08210
White7115273296
More than one race0000
Unknown or Not Reported74314
08

Study locations

73 sites
  • City of Hope Comprehensive Cancer Center
    Duarte, California 91010, United States
  • Yale Cancer Center; Medical Oncology
    New Haven, Connecticut 06520, United States
  • Georgetown University
    Washington, District of Columbia 20007, United States
  • Florida Cancer Specialists; SCRI
    Fort Myers, Florida 33901, United States
  • Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy)
    Jacksonville, Florida 32256, United States
  • Florida Cancer Specialists.
    Saint Petersburg, Florida 33705, United States
  • Ingalls Cancer Research Center
    Harvey, Illinois 60426, United States
  • Southdale Cancer Clinic U of M Medical Center, Fairview- Edina
    Edina, Minnesota 55435, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • North Shore Hem Onc Associates
    East Setauket, New York 11733, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • INTEGRIS Cancer Inst of OK
    Oklahoma City, Oklahoma 73142, United States
  • University of Pittsburgh Cancer Institute; Division of Medical Oncology
    Pittsburgh, Pennsylvania 15232, United States
  • SCRI Tennessee Oncology Chattanooga
    Chattanooga, Tennessee 37404, United States
  • Sarah Cannon Research Inst.
    Nashville, Tennessee 37203, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Medical Oncology Associates
    Spokane, Washington 99208, United States
  • Port Macquarie Base Hospital;North Coast Cancer Institute
    Port Macquarie, New South Wales 2444, Australia
  • Northern Cancer Institute
    St Leonards, New South Wales 2065, Australia
  • Sydney Adventist Hospital; Clinical Trial Unit
    Sydney, New South Wales 2076, Australia
  • Monash Medical Centre; Oncology
    Clayton, Victoria 3168, Australia
  • Peninsula and South Eastern Haematology and Oncology Group
    Frankston, Victoria 3199, Australia
  • Austin Health; Cancer Clinical Trial Centre
    Heidelberg, Victoria 3084, Australia
  • Imeldaziekenhuis
    Bonheiden, 2820, Belgium
  • Cliniques Universitaires St-Luc
    Bruxelles, 1200, Belgium
  • GHdC Site Notre Dame
    Charleroi, 6000, Belgium
  • AZ Groeninge
    Kortrijk, 8500, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • Tom Baker Cancer Centre-Calgary
    Calgary, Alberta T2N 4N2, Canada
  • Cross Cancer Institute; Clinical Trials
    Edmonton, Alberta T6G 1Z2, Canada
  • BCCA-Vancouver Cancer Centre
    Vancouver, British Columbia V5Z 4E6, Canada
  • The Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • McGill University Health Center, Cedar Cancer Center
    Montreal, Quebec H3G 1A4, Canada
  • Hopital du Sacre-Coeur
    Montreal, Quebec J4B 5Z7, Canada
  • CHU de Québec
    Quebec City, Quebec G1J 1Z4, Canada
  • Queen Mary Hospital; Dept. of Clinical Oncology
    Hong Kong, Hong Kong
  • Tuen Mun Hospital; Clinical Oncology
    Hong Kong, Hong Kong
  • Prince of Wales Hosp; Dept. Of Clinical Onc
    Shatin, Hong Kong
  • Azienda Osp Uni Seconda Università Degli Studi Di Napoli; Unità Operativa Oncologia Medica
    Napoli, Campania 80131, Italy
  • A.O. Universitaria Policlinico Di Modena; Oncologia
    Modena, Emilia-Romagna 41100, Italy
  • Istit. Naz. per la Ricerca sul Cancro - Az. Osped. S. Martino
    Genova, Liguria 16132, Italy
  • Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1
    Milano, Lombardia 20133, Italy
  • Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia
    Milano, Lombardia 20162, Italy
  • IRCCS Ospedale Casa Sollievo Della Sofferenza; Oncologia
    San Giovanni Rotondo, Puglia 71013, Italy
  • A.O. Universitaria Pisana; Oncologia
    Pisa, Toscana 56100, Italy
  • National Cancer Center
    Gyeonggi-do, 10408, Korea, Republic of
  • Chonnam National University Hwasun Hospital
    Jeollanam-do, 58128, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Asan Medical Center - Oncology
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Yonsei University Health System/Severance Hospital
    Seoul, 120-752, Korea, Republic of
  • Centrum Onkologii im. Prof. F. Lukaszczyka w Bydgoszczy
    Bydgoszcz, 85-796, Poland
  • Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii
    Gdańsk, 80-214, Poland
  • Szpitale Pomorskie Sp. z o. o.
    Gdynia, 81-519, Poland
  • Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii
    Krakow, 31-531, Poland
  • Woj.Wielospecjalistyczne Centrum Onkologii i Traumatologii; Oddz.Hematologii Pododz.Chemioterapii
    Lodz, 93-513, Poland
  • Arkhangelsk Regional Clinical Oncology Dispensary
    Arkhangelsk, 163045, Russian Federation
  • N.N.Burdenko Main Military Clinical Hospital; Oncology Dept
    Moscow, 105229, Russian Federation
  • BHI of Omsk region Clinical Oncology Dispensary
    Omsk, 644013, Russian Federation
  • Hospital Univ Vall d'Hebron; Servicio de Oncologia
    Barcelona, 08035, Spain
  • Hospital Ramon y Cajal; Servicio de Oncologia
    Madrid, 28034, Spain
  • Hospital Clinico San Carlos; Servicio de Oncologia
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre; Servicio de Oncologia
    Madrid, 28041, Spain
  • Hospital de Navarra; Servicio de Oncologia
    Navarra, 31008, Spain
  • Hospital Clínico Universitario de Valencia; Servicio de Oncología
    Valencia, 46010, Spain
  • Birmingham Heartlands Hospital; Dept of Oncology
    Birmingham, B9 5SS, United Kingdom
  • Royal Marsden Hospital - Fulham; Oncology Department
    London, SW3 6JJ, United Kingdom
  • The Christie; GI Research Office
    Manchester, M20 4BX, United Kingdom
  • Churchill Hospital; Department of Oncology
    Oxford, OX3 7LE, United Kingdom
  • Queen's Hospital
    Romford, RM7 0AG, United Kingdom
  • Weston Park Hospital; Cancer Clinical Trials Centre
    Sheffield, S10 2SJ, United Kingdom
  • Royal Marsden Hospital; Dept of Medical Oncology
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Barteselli G, Goodman GR, Patel Y, Caro I, Xue C, McCallum S. Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies. Drug Saf. 2022 Dec;45(12):1491-1499. doi: 10.1007/s40264-022-01248-2. Epub 2022 Oct 30. PubMed 36310331 ↗
  • Eng C, Kim TW, Bendell J, Argiles G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F; IMblaze370 Investigators. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019 Jun;20(6):849-861. doi: 10.1016/S1470-2045(19)30027-0. Epub 2019 Apr 16. Erratum In: Lancet Oncol. 2019 Jun;20(6):e293. doi: 10.1016/S1470-2045(19)30283-9. PubMed 31003911 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Mar 2018, 20 months.

Results were first posted in Jun 2019, 1 year 3 months after primary completion.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 20 months is below that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2016
First posted
Jun 2, 2016
StartActual
Jul 5, 2016
Primary completionActual
Mar 9, 2018
CompletionActual
Dec 26, 2018
Results first posted
Jun 18, 2019
Last update
Dec 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02788279
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 2, 2016
Start date
Jul 5, 2016
Primary completion
Mar 9, 2018
Completion
Dec 26, 2018
Results posted
Jun 18, 2019
Last update
Dec 11, 2019

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atezolizumab · Cobimetinib

Start the discussion